TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07191028: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parellel-group Study to Assess the Efficacy and Safety of MLC901 (NeuroAiD™II) in Subjects With Mild to Moderate Alzheimer's Disease (AD).

Sponsor: Moleac Pte Ltd. · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 350 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$17,630,720

Rescue Site Savings

+$11,625,256

Unlock Full NCT07191028 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07191028 Rescue Dossier →